Drug Profile
NI 504
Alternative Names: NI-504Latest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator Neurimmune Therapeutics
- Class Monoclonal antibodies; Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurodegenerative disorders
Most Recent Events
- 07 Dec 2022 NI 504 is still in preclinical trials for Neurodegenerative disorders in Switzerland
- 28 Oct 2022 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in Switzerland (Parenteral)
- 18 Sep 2018 Preclinical trials in Neurodegenerative disorders in Switzerland (Parenteral)